- Home
- NML vs PACB Comparison
NML vs PACB Comparison
Compare NML & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NML | PACB |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.8M | 462.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NML | PACB |
|---|---|---|
| Price | $10.05 | $1.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 156.4K | ★ 5.7M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.32 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $7.89 | $1.09 |
| 52 Week High | $10.71 | $2.73 |
Technical Indicators
Market Signals| Indicator | NML | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 44.72 |
| Support Level | $9.69 | $1.18 |
| Resistance Level | $9.94 | $1.40 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.55 | 16.35 |
Price Performance
Historical ComparisonAbout NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.